Scilex announces commercial launch of ELYXYB in the U.S.

Scilex Holding Company announced the commercial launch of ELYXYB in the U.S. Starting today, ELYXYB is available in pharmacies to customers and supplied through their normal wholesaler and distributor channels. ELYXYB was approved by the U.S. Food and Drug Administration on May 6, 2020, for the treatment of acute migraine with or without aura in adults. Strong re-launch commercialization efforts including multiple manuscripts, five posters at American Headache Society and more than six thousand interactions with potential customers have laid the groundwork for what Scilex believes will be the successful re-introduction of ELYXYB into the outpatient marketplace.The Scilex sales force, consists of approximately 65 pain specialists who cover more than 80 percent of the physicians Scilex is targeting for ELYXYB. Since we acquired ELYXYB, our team has been executing a training and market access strategy, working closely with key customers to initiate the review process to obtain access for ELYXYB.